Effect of n-3 fatty acids on markers of brain injury and incidence of sepsis-associated delirium in septic patients

Acta Anaesthesiol Scand. 2014 Jul;58(6):689-700. doi: 10.1111/aas.12313. Epub 2014 Mar 24.

Abstract

Background: Data regarding immunomodulatory effects of parenteral n-3 fatty acids in sepsis are conflicting. In this study, the effect of administration of parenteral n-3 fatty acids on markers of brain injury, incidence of sepsis-associated delirium, and inflammatory mediators in septic patients was investigated.

Methods: Fifty patients with sepsis were randomized to receive either 2 ml/kg/day of a lipid emulsion containing highly refined fish oil (equivalent to n-3 fatty acids 0.12 mg/kg/day) during 7 days after admission to the intensive care unit or standard treatment. Markers of brain injury and inflammatory mediators were measured on days 1, 2, 3 and 7. Assessment for sepsis-associated delirium was performed daily. The primary outcome was the difference in S-100β from baseline to peak level between both the intervention and the control group, compared by t-test. Changes of all markers over time were explored in both groups, fitting a generalized estimating equations model.

Results: Mean difference in change of S-100β from baseline to peak level was 0.34 (95% CI: -0.18-0.85) between the intervention and control group, respectively (P = 0.19). We found no difference in plasma levels of S-100β, neuron-specific enolase, interleukin (IL)-6, IL-8, IL-10, and C-reactive protein between groups over time. Incidence of sepsis-associated delirium was 75% in the intervention and 71% in the control groups (risk difference 4%, 95% CI -24-31%, P = 0.796).

Conclusion: Administration of n-3 fatty acids did not affect markers of brain injury, incidence of sepsis-associated delirium, and inflammatory mediators in septic patients.

Trial registration: ClinicalTrials.gov NCT00772096.

Publication types

  • Comparative Study
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Biomarkers
  • Brain Damage, Chronic / blood
  • Brain Damage, Chronic / etiology
  • Brain Damage, Chronic / prevention & control*
  • C-Reactive Protein / analysis
  • Delirium / blood
  • Delirium / etiology
  • Delirium / prevention & control*
  • Emulsions
  • Fatty Acids, Omega-3 / administration & dosage
  • Fatty Acids, Omega-3 / adverse effects
  • Fatty Acids, Omega-3 / pharmacology
  • Fatty Acids, Omega-3 / therapeutic use*
  • Female
  • Fish Oils / administration & dosage
  • Fish Oils / adverse effects
  • Fish Oils / pharmacology
  • Fish Oils / therapeutic use*
  • Follow-Up Studies
  • Humans
  • Hypertriglyceridemia / chemically induced
  • Inflammation Mediators / blood
  • Interleukins / blood
  • Kaplan-Meier Estimate
  • Male
  • Middle Aged
  • Phosphopyruvate Hydratase / blood
  • S100 Calcium Binding Protein beta Subunit / blood
  • Sepsis / blood
  • Sepsis / complications*

Substances

  • Biomarkers
  • Emulsions
  • Fatty Acids, Omega-3
  • Fish Oils
  • Inflammation Mediators
  • Interleukins
  • S100 Calcium Binding Protein beta Subunit
  • C-Reactive Protein
  • Phosphopyruvate Hydratase

Associated data

  • ClinicalTrials.gov/NCT00772096